Nitazene Control Act of 2025
United States119th CongressHR-5415House of Representatives
Updated: Sep 16, 2025
Summary
This bill proposes to permanently classify the entire class of benzimidazole-opioids , known as nitazenes, as Schedule I controlled substances under the Controlled Substances Act. These synthetic opioids are recognized for their significant potency, with some exceeding that of fentanyl, and have emerged in the illicit drug supply contributing to overdose fatalities. The legislation aims to address their high abuse potential and lack of accepted medical use by ensuring their permanent placement in the most restrictive schedule. The bill provides a detailed structural definition for 2-benzylbenzimidazole opioids, including specific modifications and examples like etonitazene and isotonitazene, to ensure a comprehensive class-wide scheduling. This approach is intended to preemptively address the proliferation of new analogs , streamline enforcement efforts, and safeguard public health. Furthermore, any nitazene compounds previously temporarily scheduled by the DEA will automatically convert to permanent Schedule I status upon the bill's enactment, while clarifying that new research still requires proper registration.
Bill texts
All available records shown.
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
House of Representatives
All available records shown.